An introduction to EpiAxis
EpiAxis Therapeutics is a privately funded, leading epigenetics company with a focus on the treatment, diagnosis and monitoring of cancer, and the prevention of its recurrence. Our lead therapeutic candidate (EPI-111) targets the eraser enzyme lysine-specific demethylase 1 (LSD1) and has a dual mechanism to treat cancer by:
1) targeting the dormant cancer cells that seed cancer recurrence and, concurrently
2) reinvigorating exhausted immune cells.
Importantly we have demonstrated clinical proof of concept in reprogramming cancer cells by targeting LSD1 in our pioneering EPI-PRIMED clinical trial. In addition to first-in-class assets we have dominant intellectual property covering targeting of LSD1 in combination with surgery, other drugs including radiotherapy across the metastatic setting. We also have projects targeting PKC theta and PD1/PDL1.
EpiAxis was established in 2015 from research conducted by our Founding Scientist – Professor Sudha Rao, a leading epigenetic researcher. Prof Rao was initially based at the University of Canberra and is now with the QIMR Berghofer Medical Research Institute.
It’s an exciting time for EpiAxis Therapeutics, as we welcome new investors and develop additional IP.
EpiAxis Therapeutics is headed by CEO Jeremy Chrisp (left), pictured above with Founding Scientist Professor Sudha Rao and Chair Dr David Fuller.
While there have been tremendous recent advances in cancer treatment, there is still large unmet need, as cancer typically recurs after initial treatment due to the persistence of dormant cancer cells. Our first-in-class assets have dual action and target these dormant chemotherapy resistant cells while also improving the immune response against the persisting cells
Dr David Fuller MBBS
Chair at EpiAxis Therapeutics